Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials
| Autor: | Federico Germini, Daniela Mari, Anna Coerezza, Maura Marcucci, Lorenzo Bellintani, Paolo Dionigi Rossi, Luca Andreinetti, Alessandro Nobili |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
N of 1 trial
medicine.medical_specialty N-of-1 trial Analgesic Medicine (miscellaneous) Chronic pain Palmitic Acids Placebo law.invention 03 medical and health sciences Study Protocol 0302 clinical medicine Elderly Randomized controlled trial Clinical Protocols law medicine Humans Pharmacology (medical) 030212 general & internal medicine Palmitoylethanolamide Aged Polypharmacy Analgesics Cross-Over Studies business.industry Normast Bayes Theorem medicine.disease Crossover study Amides Clinical trial Ethanolamines Sample Size Physical therapy business 030217 neurology & neurosurgery Geriatric |
| Zdroj: | Trials |
| ISSN: | 1745-6215 0269-9281 |
| Popis: | Background Chronic pain in older people is highly prevalent, often underestimated, and associated with adverse outcomes. Most available analgesic drugs are often either ineffective or not tolerated, with many side effects. Palmitoylethanolamide (PEA) is an endogenous widely distributed N-acylethanolamina involved in neuroinflammation and pain-generating processes. Formulations containing ultra-micronized palmitoylethanolamide (um-PEA) are available but their effectiveness on chronic pain in highly heterogeneous geriatric patients is not clear and probably not generalizable. We planned to adopt the N-of-1 trial approach to test the effectiveness of um-PEA objectively at the individual level in our older outpatients. Methods/Design Persons 65 years or older referring to the Geriatric Unit of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan complaining of noncancer chronic pain of any origin will be eligible. Each trial will be a placebo-controlled randomized crossover trial including two um-PEA (600 mg twice a day) and placebo treatment pairs. The um-PEA or placebo 3-week periods will be separated by 2-week washout intervals to overcome possible carryover effects. Pain intensity, need of on-demand analgesic medications, and impact on daily activities will be evaluated. Cognitively impaired patients will be eligible as long as an expression of pain can be recognized and its frequency assessed by a caregiver. Trial results will be discussed with the patient or caregiver and the treating physician to decide whether to continue the treatment. The impact of the N-of-1 approach on the physician’s management plan and confidence will be assessed. We will secondarily meta-analyze the performed N-of-1 trials to obtain an estimate of the average effect of um-PEA compared with placebo using a frequentist and Bayesian approach. Discussion While pursuing an ultimate clinical objective, i.e. to empirically and objectively decide the best treatment choice for an individual older patient with chronic pain, these series of geriatric N-of-1 trials on PEA will bring the principles of evidence-based medicine into the care of patients not usually represented in conventional randomized controlled trials, and realize a patient-centered outcome approach necessary to improve appropriate prescribing in elderly patients with multimorbidity and polypharmacy. Trial registration ClinicalTrials.gov NCT02699281. Registered on 3 March 2016. Electronic supplementary material The online version of this article (doi:10.1186/s13063-016-1496-9) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|